Kunming Pharmaceutical Corporation

Kunming, China

Kunming Pharmaceutical Corporation

Kunming, China
SEARCH FILTERS
Time filter
Source Type

Patent
Kunming Pharmaceutical Corporation | Date: 2015-10-21

Disclosed are an arteannuin cyclodextrin conjugate and a preparation method thereof. The present invention relates to the field of pharmaceutical synthesis. The arteannuin cyclodextrin conjugate in the present invention uses cyclodextrin as a carrier, and molecules of an arteannuin compound are connected by using an amido bond formed between a carboxyl group of the molecules of the arteannuin compound and an amido group of the cyclodextrin modified by the amido group. Compared with arteannuin and dihydroartemisinin, the arteannuin cyclodextrin conjugate in the present invention has more hydrophilic active groups, and has good biocompatibility, better water solubility and high bioavailability. In another aspect, the arteannuin cyclodextrin conjugate in the present invention has anticancer target feature, and specifically for colorectal cancer cells, the arteannuin cyclodextrin conjugate can effectively enter the body of a patient, gather around target cancer cells at a top priority, and selectively induce rectum cancer cells of a human body to die, thereby improving pharmacodynamic effects and reducing toxic or side effects. The method for preparing the arteannuin cyclodextrin conjugate in the present invention features simple operations, easy availability of materials and moderate reaction conditions, and can be used for manufacturing a great amount of the arteannuin cyclodextrin conjugate.


Patent
Kunming Pharmaceutical Corporation | Date: 2014-04-09

The invention discloses mangiferin aglycone crystal form I. X-ray powder diffraction analysis, DSC analysis, TG-DTA analysis, IR analysis and HPLC analysis show that mangiferin aglycone crystal form I is a new crystal form. Mangiferin aglycone crystal form I in comparison with existing mangiferin aglycone has high purity, high stability in light, humidity and heat, high bioavailability. The invention also provides preparation method of mangiferin aglycone crystal form I, pharmaceutical composition and dosage form comprising the same.


Patent
Kunming Pharmaceutical Corporation | Date: 2015-10-07

An artemether-containing pharmaceutical composition, a preparation, and a use thereof in preparation of a medicament for treatment of tumor. The pharmaceutical composition comprises either artemether or dihydroartemisinin and iron, where the weight ratio of the two is 1:0.0-1:2.


Patent
Kunming Pharmaceutical Corporation | Date: 2015-10-07

Disclosed is a use of artemether in the preparation of a drug for treating leukemia. The drug is an artemether injection or lyophilized powder for injection, and is prepared with the artemether and a water soluble cyclodextrin derivative in a weight ratio of 1:30-70.


Patent
Kunming Pharmaceutical Corporation | Date: 2015-05-06

Provided is a method for preparing scutellarin aglycone. In the method, 5,6,7,4-tetramethoxy flavone is used as raw material, and high purity scutellarin aglycone is obtained through four steps of demethylation, acylation, hydrolyzation, and refinement. The preparing method is characterized by a low synthesis cost, a short line, and a high reaction yield, and the product is easily purified, can implement industrialized production, and has a desired industrial application prospect.


Patent
Kunming Pharmaceutical Corporation | Date: 2016-01-20

Disclosed are a cyclodextrin carrier-based arteannuin compound conjugate and a preparing method thereof. Molecules of an arteannuin compound are connected by using an ester bond formed between a carboxyl group of the molecules of the arteannuin compound and a hydroxyl group of the cyclodextrin.


Patent
Kunming Pharmaceutical Corporation | Date: 2015-02-25

The present invention relates to the field of drug synthesis. Disclosed is a method for preparing 5,6,4-trihydroxyflavone-7-O-D-glucuronic acid. The method for preparing 5,6,4-trihydroxyflavone-7-O-D-glucuronic acid of the present invention uses 5,6,7,4-tetrahydroxyflavone as a raw material and adopts a new synthetic route to obtain high-purity 5,6,4-trihydroxyflavone-7-O-D-glucuronic acid through an acylation reaction, a glycosylation reaction, and two-step hydrolysis. The preparing method of the present invention has a short synthetic route, low cost, and high reaction yield, the product is easy for purification, and the method is applicable to industrial production of 5,6,4-trihydroxyflavone-7-O-D-glucuronic acid.


Disclosed is an application of piceatannol-3-O--D-glucopyranoside in the preparation of medicaments for improving microcirculation block. The medicaments comprise piceatannol-3-O--D-glucopyranoside of formula (I) as active ingredients:


The present invention relates to the technical field of medicine, and relates specifically to a method for dissolving a flavonoid compound, a carbon glycoside compound, or a stilbene compound and a method for preparing an injection or a powder for injection. The method: the flavonoid compound, the carbon glycoside compound, or the stilbene compound is mixed with a solubilizer to acquire a reactant; when water for injection is heated and stirred in a vacuum, the reactant is added under the protection of nitrogen or argon to acquire a product. The dissolution speed of the method is fast, redissolution tests show that a freeze-dried powder that is acquired when a water-soluble medicament acquired is freeze-dried can dissolve completely in just five seconds, a significant increase in redissolution speed compared with a control group; also, the stability is great, and a medicinal requirement for clinical emergencies is satisfied.


The present invention relates to the field of medicine, and relates specifically to an application of gastrodin as a solubilizer and a method for preparing an injection or a powder for injection. The dissolution speed of the method is fast, redissolution tests show that the powder for injection prepared and acquired by using gastrodin as the solubilizer respectively for a flavonoid compound, a carbon glycoside compound, and a stilbene compound dissolves completely in just five seconds, a significant increase in the redissolution speed compared with a control group; also, the stability is great, and a medicinal requirement for clinical emergencies is satisfied.

Loading Kunming Pharmaceutical Corporation collaborators
Loading Kunming Pharmaceutical Corporation collaborators